NOVN.CH

115.74

+2.1%↑

LONN.CH

479.9

+1.52%↑

SDZ.CH

62.48

+1.59%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

70.65

+3.74%↑

NOVN.CH

115.74

+2.1%↑

LONN.CH

479.9

+1.52%↑

SDZ.CH

62.48

+1.59%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

70.65

+3.74%↑

NOVN.CH

115.74

+2.1%↑

LONN.CH

479.9

+1.52%↑

SDZ.CH

62.48

+1.59%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

70.65

+3.74%↑

NOVN.CH

115.74

+2.1%↑

LONN.CH

479.9

+1.52%↑

SDZ.CH

62.48

+1.59%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

70.65

+3.74%↑

NOVN.CH

115.74

+2.1%↑

LONN.CH

479.9

+1.52%↑

SDZ.CH

62.48

+1.59%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

70.65

+3.74%↑

Search

Roche Holding AG

Closed

SectorHealthcare

325.6 0.74

Overview

Share price change

24h

Current

Min

325.4

Max

326.6

Key metrics

By Trading Economics

Income

1.8B

5.5B

Sales

15B

31B

P/E

Sector Avg

20.461

67.147

Dividend yield

2.97

Profit margin

17.892

Employees

103,249

EBITDA

5.1B

12B

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.97%

2.36%

Market Stats

By TradingEconomics

Market Cap

-28B

261B

Previous open

324.86

Previous close

325.6

News Sentiment

By Acuity

7%

93%

2 / 347 Healthcare

Roche Holding AG Chart

Past performance is not a reliable indicator of future results.

Related News

23 Apr 2026, 07:46 UTC

Earnings

Roche Backs Full-Year View as Quarterly Sales Rise -- Update

23 Apr 2026, 05:40 UTC

Earnings

Roche Backs Full-Year View as Quarterly Sales Rise

9 Mar 2026, 16:43 UTC

Major Market Movers

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

9 Mar 2026, 15:44 UTC

Major Market Movers

Correction to Roche Shares Article

9 Mar 2026, 09:51 UTC

Major Market Movers

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

6 Mar 2026, 09:24 UTC

Major Market Movers

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

29 Jan 2026, 10:07 UTC

Earnings

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29 Jan 2026, 07:07 UTC

Earnings

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

27 Apr 2026, 09:54 UTC

Market Talk

Roche's Vabysmo U.S. Recovery Will Be Key -- Market Talk

23 Apr 2026, 08:10 UTC

Market Talk
Earnings

Roche Reports In Line Sales Figures -- Market Talk

23 Apr 2026, 05:04 UTC

Earnings

Roche Backs 2026 View

23 Apr 2026, 05:04 UTC

Earnings

Roche Diagnostics Division 1Q Sales Up at 3% Constant Currency

23 Apr 2026, 05:03 UTC

Earnings

Roche Pharmaceutical Division 1Q Sales Up 7% at Constant Currency

23 Apr 2026, 05:02 UTC

Earnings

Roche 1Q Group Sales Up 6% at Constant Currency

23 Apr 2026, 05:02 UTC

Earnings

Analysts Saw Roche 1Q Sales at CHF14.73B

23 Apr 2026, 05:01 UTC

Earnings

Roche 1Q Sales CHF14.72B

10 Apr 2026, 11:28 UTC

Market Talk

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

10 Apr 2026, 11:17 UTC

Market Talk

Roche to Face Significant Currency Headwinds -- Market Talk

11 Mar 2026, 10:57 UTC

Market Talk

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

9 Mar 2026, 09:43 UTC

Hot Stocks

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

6 Mar 2026, 07:22 UTC

Market Talk

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

3 Mar 2026, 07:22 UTC

Market Talk

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2 Mar 2026, 14:21 UTC

Market Talk

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

29 Jan 2026, 11:40 UTC

Market Talk
Earnings

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29 Jan 2026, 06:05 UTC

Earnings

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29 Jan 2026, 06:04 UTC

Earnings

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29 Jan 2026, 06:03 UTC

Earnings

Roche Issues 2026 View

29 Jan 2026, 06:02 UTC

Earnings

Analysts Saw 2025 Core EPS at CHF19.70

29 Jan 2026, 06:02 UTC

Earnings

Roche: 2025 Core EPS CHF19.46

29 Jan 2026, 06:01 UTC

Earnings

Analysts Had Seen 2025 Sales At CHF61.47B

Peer Comparison

Price change

Roche Holding AG Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Sentiment

By Acuity

2 / 347 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat